Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: Ascent CEO Colin Hutchinson with latest on review and permitting Watch Here

EXCLUSIVE: Ascent CEO Colin Hutchinson with latest on review and permitting


Angle Share Price (AGL)



Share Price Information for Angle (AGL)


Share Price: 51.20Bid: 50.40Ask: 52.00Change: 0.00 (0.00%)No Movement on Angle
Spread: 1.60Spread as %: 3.17%Open: 51.00High: 51.20Low: 51.00Yesterday’s Close: 51.20

Angle Plc Ord 10P

Angle is listed in the FTSE AIM All-Share
Angle is part of the Support sector






Share Price SpacerPrice
51.20
Share Price SpacerBid
50.40
Share Price SpacerAsk
52.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
56,110
Share Price SpacerOpen
51.00
Share Price SpacerHigh
51.20
Share Price SpacerLow
51.00
Share Price SpacerClose
51.20
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 142.49m £72.95m 5,000

52 Week High 60.50 52 Week High Date 9-JUL-2018
52 Week Low 32.25 52 Week Low Date 8-SEP-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
9 41,526 0 -5.074 -10.09 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

15-Aug-18
15:50:43
50.80
9,400
Sell* 
50.40
52.00
4,775
Trade Type:
Ordinary

15-Aug-18
15:44:34
50.50
5,000
Sell* 
50.40
52.00
2,525
Trade Type:
Ordinary

15-Aug-18
15:44:34
50.45
-5,000
Sell* 
50.40
52.00
-2,523
Trade Type:
Ordinary
Deletion




View more Angle trades >>

Directors Deals for Angle (AGL)
Trade DateActionNotifierPriceCurrencyAmountHolding
26-Oct-16Buy
Trade Notifier Information for Angle
Andrew D Newland held the position of CEO at Angle at the time of this trade.
 Andrew D Newland
57GBX1,350,0007054686
30-Apr-16Notification of Holding
Trade Notifier Information for Angle
Ian F Griffiths held the position of Finance Director at Angle at the time of this trade.
 Ian F Griffiths
00559546
30-Apr-16Notification of Holding
Trade Notifier Information for Angle
Garth Selvey held the position of Chairman at Angle at the time of this trade.
 Garth Selvey
0020000
View more Angle directors dealings >>


Malachi
Posts: 263
Opinion:No Opinion
Price:51.00
Daily Mail Article
Wed 08:52
Apheresis is a hassle. Cell lines have been cultured from Parsortix derived CTCs. It will be the method of choice if cell culture can be achieved consistently. IMO etc,.
Chazzy2
Posts: 589
Opinion:No Opinion
Price:51.00
RE: Daily mail article
Tue 19:56
Many thanks for your detailed research Seeingtom. The Mail article was very vague I must admit as to what CTC type system it was and on the face of it the Parsortix seemed to tick all the boxes from the information given.
There do seem to be several other CTC systems around but Angle appears to be steps ahead of the competition in terms of the recognition it is receiving from the major KOLs.
Drums
Posts: 184
Opinion:No Opinion
Price:51.00
RE: Daily mail article
Tue 11:28
Thank you for taking the time to explain all that, Seeingtom. That certainly clears up any confusion regarding the Mail's article and the use of Parsotix.
seeingtom
Posts: 196
Opinion:No Opinion
Price:51.00
RE: Daily mail article
Tue 10:03
Part 2/2
The question is, does this matter?
Well, it depends. You'd obviously prefer a simple blood test than to put a patient through apheresis. It is cheaper, quicker, easier and less stressful. You are only going to use apheresis if you can't get enough CTCs with the normal blood test. Parsortix has, so far, had a lot of success being used on normal blood samples and apheresis would appear not to be necessary in a large number of cases.
Some other CTC capture techniques may be less efficient so may benefit from running on apheresis product rather than normal blood samples. Some types of cancer may produce very low numbers of CTCs, even compared to other types of cancers, so in those cases, there might be benefit to using apheresis product rather than normal blood but you still need to capture the CTCs from the apheresis product and as far as I know, Parsortix could be used to capture the CTCs from the apheresis product just as it can be from the blood. Apheresis product is really just blood with some of the blood cells removed. Likewise, depending on the analysis the scientist/doctor wants to do, they might want to have more CTCs for analysis so they may choose to use apheresis to get those extra CTCs but, again, they still need to capture the CTCs and that might be using Parsortix.

Warnings: I am not a doctor or a practicing scientist. My posts should not be taken as expert opinion. My posts are merely my own personal opinion from having read around the Mail Research and others should do their own background reading and form their own opinions. Further, I have a large investment in Angle and so am not independent and may not be objective. The Mail Research can be viewed here: http://clincancerres.aacrjournals.org/content/early/2018/08/08/1078-0432.CCR-18-0862
seeingtom
Posts: 196
Opinion:No Opinion
Price:51.00
RE: Daily mail article
Tue 09:48
Part1/2
Thanks Chazzy2. The Daily Mail article is a good spot and it was interesting to dig out what had actually been done... which wasn't really as represented in the Daily Mail article.
Cancers shed cells known as CTCs into the bloodstream and if these can be captured then they can be analysed to gain information about the source cancer and this information might then be able to be used to detect the cancer, assess whether the cancer is one that requires treatment, work out which treatments will be effective on the cancer, monitor progress of treatment, detect changes in the cancer that mean treatment needs to change. Capturing these CTCs from the bloodstream is very difficult as for every CTC, there are hundreds of millions of other cells in the blood... Angle's Parsortix is a CTC capture product and there are others.
Parsortix, like other CTC capture technologies, is normally used on blood extracted in small amounts in a normal blood test, like the one that your GP gives you. This has the advantage of being quick, cheap and easy. The key difference in the research paper sited by the Daily Mail ("the Mail Research") is that instead of using the CTC capture technology on a blood sample, they used on the product from apheresis. What does that mean? Well, instead of just having a small blood sample taken like when you go to your GP, you need to go somewhere that has an apheresis machine. Two tubes are put into you, one for taking blood out and one for putting it back. Your blood goes out, passes through a centrifuge to extract one portion of the blood and then the remainder of the blood is returned to your body. In the Mail Research, patients were hooked up to the apheresis machine for between 90 minutes and 160 minutes. The centrifuge in the apheresis machine does NOT produce a pure CTC sample or anything close, it mainly extracts stuff other than CTCs, so the product still needs to be put through a CTC capture technique in order to separate the CTCs. The idea is that using the apheresis means you search through a lot more blood so the apheresis sample will have more CTCs in it than a normal blood sample would.The question is, does this matter?
Well, it depends. You'd obviously prefer a simple blood test than to put a patient through apheresis. It is cheaper, quicker, easier and less stressful. You are only going to use apheresis if you can't get enough CTCs with the normal blood test. Parsortix has, so far, had a lot of success being used on normal blood samples and apheresis would appear not to be necessary in a large number of cases.
Some other CTC capture techniques may be less efficient so may benefit from running on apheresis product rather than normal blood samples. (continued)
View more share chat for Angle (AGL) >>




Angle Plc Ord 10P home pageWebsite: Angle Plc Ord 10P
Website Description: ANGLEplc.com



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.